Population Diagnostics, Inc. To Discuss Autism Diagnostic Breakthroughs at the 2007 Life Sciences Industry Summit
Posted on: Monday, 11 June 2007, 12:00 CDT
Population Diagnostics, Inc. announced today that Jim Chinitz, the company's CEO, will present a corporate overview at the 2007 Life Sciences Industry Summit to be held on June 14th at the Huntington Hilton in Melville, NY. Mr. Chinitz is an invited speaker by the sponsors, the Long Island Life Sciences Initiative (LILSI) and the New York State Center for Biotechnology. The overview will emphasize their novel approach to revealing causative biomarkers for human disease, which are the key ingredients to developing DNA-based diagnostics and personalized medicine tests with the highest level of clinical value. The presentation will include information about its prototype platform, which has revealed causative biomarkers for Autism, paving the way for the development of a screening test.
About Population Diagnostics, Inc.
The company (www.populationdiagnostics.com) has developed a proprietary platform for the rapid and systematic discovery of "causative" genetic mutations linked to complex disease. Building on its novel technology, Population Diagnostics is focused on the development and the direct marketing of diagnostic tests in medical markets with unmet needs. Tests for Autism, Alzheimer's, Parkinson's, Diabetes, Risk of Stroke and others represent the company's pipeline. Additionally, the company is engaged with pharmaceutical companies interested in revealing causative biomarkers which will be used to selectively identify patients who will benefit the most from a drug, or to exclude those who are most likely to experience a serious adverse effect. "Causative" mutations are the only biomarkers which can be used to develop predictive tests because they represent certainty that the disease is present or it will eventually develop in a patient. In contrast, alternative technologies which represent the status quo only reveal "predisposition" or "risk factor" indicators, which give false hopes to laypeople, cause patients and physicians to make baseless decisions, and therefore are not suitable for developing and marketing diagnostic tests.
Contact: Population Diagnostics, Inc. 516-316-5895 Email Contact
SOURCE: Population Diagnostics, Inc.
Source: MARKET WIRE
Related Articles
- Ion Mobility Diagnostic Test From Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
- Power3 Medical Initiates Three Hundred Patient Clinical Validation Study of Its Nuropro(R) Diagnostic Test for Alzheimer's and Parkinson's Disease
- Panacea Pharmaceuticals Initiates GMP Manufacturing of Prostate Cancer Diagnostic Test Kits
- BioServe and Phenomenome Discoveries Develop Novel Diagnostic Test for Colorectal Cancer
- In 2009 Exonhit Aims to Ask for Market Clearance in Europe for a Blood Diagnostic Test for Alzheimer's Disease
- Vitalea Science, Inc. Announces Grant Award for Phase-I Development of a Diagnostic Test Utilizing Accelerator Mass Spectrometry and Microdosing Technologies
- Quest Diagnostics Completes Acquisition of Focus Diagnostics, Inc., A World Leader in Infectious Disease Testing
- NCGR Collaborates With Duke University Medical Center, Henry Ford Hospital, Eli Lilly and Co., INCAPS and ProSanos to Develop Novel Diagnostic Tests for Sepsis and Pneumonia
- College Park-Based Innovative Biosensors Closing in on Diagnostic Test for Mad Cow Disease
- Better Diagnostic Test for Prostate Disease Likel
 |
 |
User Comments (0)
RSS Feeds